The Effectiveness of Cannabinoids in the Treatment of Posttraumatic Stress Disorder (PTSD): A Systematic Review

References

• Ballard, M. E., Bedi, G., & de Wit, H. (2012). Effects of delta-9-tetrahydrocannabinol on evaluation of emotional images. Journal of Psychopharmacology, 26(10), 1289–1298. doi:10.1177/0269881112446530
   PubMed Web of Science ®Google Scholar
• Bergamaschi, M. M., Queiroz, R. H. C., Chagas, M. H. N., de Oliveira, D. C. G., De Martinis, B. S., Kapczinski, F., … Crippa, J. A. S. (2011). Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology, 36(6), 1219–1226. doi:10.1038/npp.2011.6
   PubMed Web of Science ®Google Scholar
• Bergamaschi, M. M., Queiroz, R. H. C., Zuardi, A. W., & Crippa, A. S. (2011). Safety and side effects of cannabidiol, a Cannabis sativa constituent. Current Drug Safety, 6(4), 237–249.
   PubMedGoogle Scholar
• Bhattacharyya, S., Morrison, P. D., Fusar-Poli, P., Martin-Santos, R., Borgwardt, S., Winton-Brown, T., … McGuire, P. K. (2010). Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology, 35(3), 764–774. doi:10.1038/npp.2009.184
   PubMed Web of Science ®Google Scholar
• Bisogno, T., Hanuš, L., De Petrocellis, L., Tchilibon, S., Ponde, D. E., Brandi, I., … Di Marzo, V. (2001). Molecular targets for cannabidiol and its synthetic analogues: Effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. British Journal of Pharmacology, 134(4), 845–852. doi:10.1038/sj.bjp.0704327
   PubMed Web of Science ®Google Scholar
• Blake, D. D., Weathers, F. W., Nagy, L. M., Kaloupek, D. G., Gusman, F. D., Charney, D. S., & Keane, T. M. (1995). The development of a clinician-administered PTSD scale. Journal of Traumatic Stress, 8(1), 75–90.
   PubMed Web of Science ®Google Scholar
• Blanchard, E. B., Jones-Alexander, J., Buckley, T. C., & Forneris, C. A. (1996). Psychometric properties of the PTSD Checklist (PCL). Behaviour Research and Therapy, 34(8), 669–673. doi:10.1016/0005-7967(96)00033-2
   PubMed Web of Science ®Google Scholar
• Bloomfield, M. A., Ashok, A. H., Volkow, N. D., & Howes, O. D. J. N. (2016). The effects of Δ9-tetrahydrocannabinol on the dopamine system. Nature, 539(7629), 369doi:10.1038/nature20153
   PubMed Web of Science ®Google Scholar
• Bloomfield, M. A. P., Hindocha, C., Green, S. F., Wall, M. B., Lees, R., Petrilli, K., … Freeman, T. P. (2018). The neuropsychopharmacology of cannabis: A review of human imaging studies. Pharmacology and Therapeutics, 195, 132–161. doi:10.1016/j.pharmthera.2018.10.006
   PubMed Web of Science ®Google Scholar
• Boden, M. T., Babson, K. A., Vujanovic, A. A., Short, N. A., & Bonn‐Miller, M. O. (2013). Posttraumatic stress disorder and cannabis use characteristics among military veterans with cannabis dependence. The American Journal on Addictions, 22(3), 277–284. doi:10.1111/j.1521-0391.2012.12018.x
   PubMed Web of Science ®Google Scholar
• Bohnert, K. M., Perron, B. E., Ashrafioun, L., Kleinberg, F., Jannausch, M., & Ilgen, M. A. (2014). Positive posttraumatic stress disorder screens among first-time medical cannabis patients: Prevalence and association with other substance use. Addictive Behaviors, 39(10), 1414–1417. doi:10.1016/j.addbeh.2014.05.022
   PubMed Web of Science ®Google Scholar
• Bonn-Miller, M. O., Babson, K. A., & Vandrey, R. (2014). Using cannabis to help you sleep: Heightened frequency of medical cannabis use among those with PTSD. Drug and Alcohol Dependence, 136, 162–165. doi:10.1016/j.drugalcdep.2013.12.008
   PubMed Web of Science ®Google Scholar
• Bonn-Miller, M. O., Boden, M. T., Bucossi, M. M., & Babson, K. A. (2014). Self-reported cannabis use characteristics, patterns and helpfulness among medical cannabis users. The American Journal of Drug and Alcohol Abuse, 40(1), 23–30. doi:10.3109/00952990.2013.821477
   PubMed Web of Science ®Google Scholar
• Bonn-Miller, M. O., Loflin, M. J. E., Thomas, B. F., Marcu, J. P., Hyke, T., & Vandrey, R. (2017). Labeling accuracy of cannabidiol extracts sold online. JAMA, 318(17), 1708–1709. doi:10.1001/jama.2017.11909
   PubMed Web of Science ®Google Scholar
• Bossong, M. G., van Hell, H. H., Jager, G., Kahn, R. S., Ramsey, N. F., & Jansma, J. M. (2013). The endocannabinoid system and emotional processing: A pharmacological fMRI study with 9-tetrahydrocannabinol. European Neuropsychopharmacology, 23(12), 1687–1697. doi:10.1016/j.euroneuro.2013.06.009
   PubMed Web of Science ®Google Scholar
• Bremner, J. D., Krystal, J. H., Charney, D. S., & Southwick, S. M. (1996). Neural mechanisms in dissociative amnesia for childhood abuse. The American Journal of Psychiatry, 153(7), 71.
   PubMed Web of Science ®Google Scholar
• Bremner, J. D., Southwick, S. M., Darnell, A., & Charney, D. S. (1996). Chronic PTSD in Vietnam combat veterans: Course of illness and substance abuse. American Journal of Psychiatry, 153(3), 369–375. doi:10.1176/ajp.153.3.369
   PubMed Web of Science ®Google Scholar
• Brewin, C. (2001). Memory processes in post-traumatic stress disorder. International Review of Psychiatry, 13(3), 159–163. doi:10.1080/09540260120074019
   Web of Science ®Google Scholar
• Brewin, C. (2003). Posttraumatic stress disorder: Malady or myth? Yale University Press.
   Google Scholar
• Brewin, C. R., Cloitre, M., Hyland, P., Shevlin, M., Maercker, A., Bryant, R. A., … Reed, G. M. (2017). A review of current evidence regarding the ICD-11 proposals for diagnosing PTSD and complex PTSD. Clinical Psychology Review, 58, 1–15. doi:10.1016/j.cpr.2017.09.001
   PubMed Web of Science ®Google Scholar
• Calignano, A., La Rana, G., Giuffrida, A., & Piomelli, D. (1998). Control of pain initiation by endogenous cannabinoids. Nature, 394(6690), 277. doi:10.1038/28393
   PubMed Web of Science ®Google Scholar
• Cameron, C., Watson, D., & Robinson, J. (2014). Use of a synthetic cannabinoid in a correctional population for posttraumatic stress disorder–related insomnia and nightmares, chronic pain, harm reduction, and other indications: A retrospective evaluation. Journal of Clinical Psychopharmacology, 34(5), 559. doi:10.1097/JCP.0000000000000180
   PubMed Web of Science ®Google Scholar
• Campos, A. C., Moreira, F. A., Gomes, F. V., Del Bel, E. A., & Guimaraes, F. S. (2012). Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philosophical Transactions of the Royal Society B: Biological Sciences, 367(1607), 3364–3378. doi:10.1098/rstb.2011.0389
   PubMed Web of Science ®Google Scholar
• Carliner, H., Brown, Q. L., Sarvet, A. L., & Hasin, D. S. (2017). Cannabis use, attitudes, and legal status in the U.S.: A review. Preventive Medicine, 104, 13–23. doi:10.1016/j.ypmed.2017.07.008
   PubMed Web of Science ®Google Scholar
• Castillo, P. E., Younts, T. J., Chávez, A. E., & Hashimotodani, Y. (2012). Endocannabinoid signaling and synaptic function. Neuron, 76(1), 70–81. doi:10.1016/j.neuron.2012.09.020
   PubMed Web of Science ®Google Scholar
• Chan, G. C.-K., Hinds, T. R., Impey, S., & Storm, D. R. (1998). Hippocampal neurotoxicity of Δ9-tetrahydrocannabinol. The Journal of Neuroscience, 18(14), 5322–5332. doi:10.1523/JNEUROSCI.18-14-05322.1998
   PubMed Web of Science ®Google Scholar
• Cohen, J. (1988). Statistical power analysis for the social sciences (2nd Ed.). Hillsdale, NJ: Lawrence Erlbaum Associates, Publishers.
   Google Scholar
• Cougle, J. R., Bonn-Miller, M. O., Vujanovic, A. A., Zvolensky, M. J., Hawkins, K. A., J.R, C., … A, H. K. (2011). Posttraumatic stress disorder and cannabis use in a nationally representative sample. Psychology of Addictive Behaviors, 25(3), 554–558. doi:10.1037/a0023076
   PubMed Web of Science ®Google Scholar
• Cousijn, J., Núñez, A. E., & Filbey, F. M. (2018). Time to acknowledge the mixed effects of cannabis on health: A summary and critical review of the NASEM 2017 report on the health effects of cannabis and cannabinoids. Addiction, 113(5), 958–966. doi:10.1111/add.14084
   PubMed Web of Science ®Google Scholar
• D'Souza, D. C., Perry, E., MacDougall, L., Ammerman, Y., Cooper, T., Wu, Y-T., … Krystal, J. H. (2004). The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: Implications for psychosis. Neuropsychopharmacology, 29(8), 1558–1572. doi:10.1038/sj.npp.1300496
   PubMed Web of Science ®Google Scholar
• Das, R. K., Kamboj, S. K., Ramadas, M., Yogan, K., Gupta, V., Redman, E., … Morgan, C. J. A. (2013). Cannabidiol enhances consolidation of explicit fear extinction in humans. Psychopharmacology, 226(4), 781–792. doi:10.1007/s00213-012-2955-y
   PubMed Web of Science ®Google Scholar
• Diamond, D. M., & Zoladz, P. R. (2016). Dysfunctional or hyperfunctional? The amygdala in posttraumatic stress disorder is the bull in the evolutionary China shop. Journal of Neuroscience Research, 94(6), 437–444. doi:10.1002/jnr.23684
   PubMed Web of Science ®Google Scholar
• Ehlers, A., & Clark, D. M. (2000). A cognitive model of posttraumatic stress disorder. Behaviour Research and Therapy, 38(4), 319–345. doi:10.1016/S0005-7967(99)00123-0
   PubMed Web of Science ®Google Scholar
• Elliott, L., Golub, A., Bennett, A., & Guarino, H. (2015). PTSD and cannabis-related coping among recent veterans in New York City. Contemporary Drug Problems, 42(1), 60–76. doi:10.1177/0091450915570309
   PubMedGoogle Scholar
• Elms, L., Shannon, S., Hughes, S., & Lewis, N. (2018). Cannabidiol in the treatment of post-traumatic stress disorder: A case series. Journal of Alternative and Complementary Medicine, 25(4), 392–397. doi:10.1089/acm.2018.0437
   PubMed Web of Science ®Google Scholar
• Elzinga, B. M., & Bremner, J. D. (2002). Are the neural substrates of memory the final common pathway in posttraumatic stress disorder (PTSD)? Journal of Affective Disorders, 70(1), 1–17. doi:10.1016/S0165-0327(01)00351-2
   PubMed Web of Science ®Google Scholar
• Etkin, A., & Wager, T. D. (2007). Functional neuroimaging of anxiety: A meta-analysis of emotional processing in PTSD, social anxiety disorder, and specific phobia. American Journal of Psychiatry, 164(10), 1476–1488. doi:10.1176/appi.ajp.2007.07030504
   PubMed Web of Science ®Google Scholar
• Felder, C. C., Veluz, J. S., Williams, H. L., Briley, E. M., & Matsuda, L. A. (1992). Cannabinoid agonists stimulate both receptor- and non-receptor-mediated signal transduction pathways in cells transfected with and expressing cannabinoid receptor clones. Molecular Pharmacology, 42(5), 838–845.
   PubMed Web of Science ®Google Scholar
• Fraser, G. A. (2009). The Use of a Synthetic Cannabinoid in the Management of Treatment–Resistant Nightmares in Posttraumatic Stress Disorder (PTSD). CNS Neuroscience & Therapeutics, 15, 84–88. doi:10.1111/j.1755-5949.2008.00071.x
   PubMed Web of Science ®Google Scholar
• Freeman, T. P., Hindocha, C., Green, S. F., & Bloomfield, M. A. P. (2019). Medicinal use of cannabis based products and cannabinoids. BMJ (Clinical Research ed.), 365, l1141. doi:10.1136/bmj.l1141
   PubMed Web of Science ®Google Scholar
• Gorka, S. M., Fitzgerald, D. A., de Wit, H., & Phan, K. L. (2015). Cannabinoid modulation of amygdala subregion functional connectivity to social signals of threat. International Journal of Neuropsychopharmacology, 18(3), pyu104. doi:10.1093/ijnp/pyu104
   Web of Science ®Google Scholar
• Greer, G. R., Grob, C. S., & Halberstadt, A. L. (2014). PTSD symptom reports of patients evaluated for the New Mexico Medical Cannabis Program. Journal of Psychoactive Drugs, 46(1), 73–77. doi:10.1080/02791072.2013.873843
   PubMed Web of Science ®Google Scholar
• Hasin, D. S. J. N. (2018). US epidemiology of cannabis use and associated problems. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology, 43(1), 195doi:10.1038/npp.2017.198
   PubMed Web of Science ®Google Scholar
• Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., de Costa, B. R., & Rice, K. C. (1990). Cannabinoid receptor localization in brain. Proceedings of the National Academy of Sciences of Sciences, 87(5), 1932–1936. doi:10.1073/pnas.87.5.1932
   PubMed Web of Science ®Google Scholar
• Higgins, J. P. T., Sterne, J. A. C., Savović, J., Page, M. J., Hróbjartsson, A., Boutron, I., Reeves, B., Eldridge, S. (2016). A revised tool for assessing risk of bias in randomized trials. In: Chandler, J., McKenzie, J., Boutron, I., Welch, V. (editors). Cochrane Methods. Cochrane Database of Systematic Reviews, 10 (Suppl 1). doi:10.1002/14651858.CD201601.
   Google Scholar
• Hill, M. N., Miller, G. E., Carrier, E. J., Gorzalka, B. B., & Hillard, C. J. (2009). Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress. Psychoneuroendocrinology, 34(8), 1257–1262. doi:10.1016/j.psyneuen.2009.03.013
   PubMed Web of Science ®Google Scholar
• Hill, M. N., & Patel, S. (2013). Translational evidence for the involvement of the endocannabinoid system in stress-related psychiatric illnesses. Biology of Mood & Anxiety Disorders, 3(1), 19. doi:10.1186/2045-5380-3-19
   PubMedGoogle Scholar
• Hillard, C. J., Weinlander, K. M., & Stuhr, K. L. (2012). Contributions of endocannabinoid signaling to psychiatric disorders in humans: Genetic and biochemical evidence. Neuroscience, 204, 207–229. doi:10.1016/j.neuroscience.2011.11.020
   PubMed Web of Science ®Google Scholar
• Hindocha, C., Freeman, T. P., Schafer, G., Gardener, C., Das, R. K., Morgan, C. J., & Curran, H. V. (2015). Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: A randomised, double-blind, placebo-controlled study in cannabis users. European Neuropsychopharmacology, 25(3), 325–334. doi:10.1016/j.euroneuro.2014.11.014
   PubMed Web of Science ®Google Scholar
• Iffland, K., & Grotenhermen, F. (2017). An update on safety and side effects of cannabidiol: A review of clinical data and relevant animal studies. Cannabis and Cannabinoid Research, 2(1), 139–154. doi:10.1089/can.2016.0034
   PubMedGoogle Scholar
• Jetly, R., Heber, A., Fraser, G., Boisvert, D. (2015). The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: A preliminary randomized, double-blind, placebo-controlled cross-over design study. Psychoneuroendocrinology, 51, 585–588. doi:10.1016/j.psyneuen.2014.11.002
   PubMed Web of Science ®Google Scholar
• Kansagara, D., O'Neil, M., Nugent, S., Freeman, M., Low, A., Kondo, K., … Paynter, R. (2017). Benefits and harms of cannabis in chronic pain or post-traumatic stress disorder: A systematic review. Washington (DC): Department of Veterans Affairs.
   Google Scholar
• Karam, E. G., Friedman, M. J., Hill, E. D., Kessler, R. C., McLaughlin, K. A., Petukhova, M., … Koenen, K. C. (2014). Cumulative traumas and risk thresholds: 12-month PTSD in the World Mental Health (WMH) surveys. Depression and Anxiety, 31(2), 130–142. doi:10.1002/da.22169
   PubMed Web of Science ®Google Scholar
• Kathmann, M., Flau, K., Redmer, A., Trankle, C., & Schlicker, E. (2006). Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors. Naunyn-Schmiedeberg's Archives of Pharmacology, 372(5), 354–361. doi:10.1007/s00210-006-0033-x
   PubMed Web of Science ®Google Scholar
• Kessler, R. C., Sonnega, A., Bromet, E., Hughes, M., & Nelson, C. B. (1995). Posttraumatic stress disorder in the National Comorbidity Survey. Archives of General Psychiatry, 52(12), 1048–1060. doi:10.1001/archpsyc.1995.03950240066012
   PubMed Web of Science ®Google Scholar
• Krystal, J. H., Rosenheck, R. A., & Cramer, J. A. (2011). Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service–related PTSD: A randomized trial. JAMA, 306(5), 493–502. doi:10.1001/jama.2011.1080
   PubMed Web of Science ®Google Scholar
• Laprairie, R. B., Bagher, A. M., Kelly, M. E. M., Denovan-Wright, E. M. (2015). Cannabidiol is a negative allosteric modulator of the cannabinoid CB(1) receptor. British Journal of Pharmacology, 172(20), 4790–4805. doi:10.1111/bph.13250
   PubMed Web of Science ®Google Scholar
• LeDoux, J. (2007). The amygdala. Current Biology, 17(20), R868–R874. doi:10.1016/j.cub.2007.08.005
   PubMed Web of Science ®Google Scholar
• National Conferences of State Legislature. (2019). Marijuana overview. Retrieved from http://www.ncsl.org/research/civil-and-criminal-justice/marijuana-overview.aspx
   Google Scholar
• Lindley, S. E., Carlson, E., & Sheikh, J. (2000). Psychotic symptoms in posttraumatic stress disorder. CNS Spectrums, 5(9), 52–57. doi:10.1017/S1092852900021659
   PubMedGoogle Scholar
• Loflin, M., Babson, K. A., & Bonn-Miller, M. O. (2017). Cannabinoids as therapeutic for PTSD. Current Opinion in Psychology, 14, 78–83. doi:10.1016/j.copsyc.2016.12.001
   PubMed Web of Science ®Google Scholar
• Loflin, M., Earleywine, M., & Bonn-Miller, M. (2017). Medicinal versus recreational cannabis use: Patterns of cannabis use, alcohol use, and cued-arousal among veterans who screen positive for PTSD. Addictive Behaviors, 68, 18–23. doi:10.1016/j.addbeh.2017.01.008
   PubMed Web of Science ®Google Scholar
• Mashiah, M. (2012). Medical cannabis as treatment for chronic combat PTSD: Promising results in an open pilot study. Paper presented at the Patients Out of Time Conference, Tucson, AZ, April 28, 2012.
   Google Scholar
• Metrik, J., Bassett, S. S., Aston, E. R., Jackson, K. M., & Borsari, B. (2018). Medicinal versus recreational cannabis use among returning veterans. Translational Issues in Psychological Science, 4(1), 6–20. doi:10.1037/tps0000133
   PubMedGoogle Scholar
• Moher, D. (1998). CONSORT: An evolving tool to help improve the quality of reports of randomized controlled trials. Consolidated Standards of Reporting Trials. JAMA, 279(18), 1489–1491. doi:10.1001/jama.279.18.1489
   PubMed Web of Science ®Google Scholar
• Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G, & PRISMA Group. (2009). Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS One, 6(7), e10000097. doi:10.1371/journal.pmed.1000097
   Google Scholar
• Morena, M., Patel, S., Bains, J. S., & Hill, M. N. (2016). Neurobiological interactions between stress and the endocannabinoid system. Neuropsychopharmacology, 41(1), 80. doi:10.1038/npp.2015.166
   PubMed Web of Science ®Google Scholar
• Murad, M. H., Sultan, S., Haffar, S., & Bazerbachi, F. (2018). Methodological quality and synthesis of case series and case reports. BMJ Evidence-Based Medicine, 23(2), 60–63. doi:10.1136/bmjebm-2017-110853
   PubMedGoogle Scholar
• Mustonen, A., Niemelä, S., Nordström, T., Murray, G. K., Mäki, P., Jääskeläinen, E., & Miettunen, J. (2018). Adolescent cannabis use, baseline prodromal symptoms and the risk of psychosis. The British Journal of Psychiatry, 212(4), 227–233. doi:10.1192/bjp.2017.52
   PubMed Web of Science ®Google Scholar
• National Academies of Sciences & Medicine. (2017). The health effects of cannabis and cannabinoids: The current state of evidence and recommendations for research: National Academies Press. Washington, DC.
   Google Scholar
• Neumeister, A., Normandin, M. D., Pietrzak, R. H., Piomelli, D., Zheng, M. Q., Gujarro-Anton, A., … Huang, Y. (2013). Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: A positron emission tomography study. Molecular Psychiatry, 18(9), 1034–1040. doi:10.1038/mp.2013.61
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. (2018). Post traumatic stress disorder (NICE Guidance No. NG116). Retrieved from https://www.nice.org.uk/guidance/ng116
   Google Scholar
• O'Neil, M. E., Nugent, S. M., Morasco, B. J., Freeman, M., Low, A., Kondo, K., … D, K. (2017). Benefits and harms of plant-based cannabis for posttraumatic stress disorder. Annals of Internal Medicine, 167(5), 332–340. doi:10.7326/M17-0477
   PubMed Web of Science ®Google Scholar
• Passie, T., Emrich, H. M., Karst, M., Brandt, S. D., & Halpern, J. H. (2012). Mitigation of post-traumatic stress symptoms by Cannabis resin: A review of the clinical and neurobiological evidence. Drug Testing and Analysis, 4(7–8), 649–659. doi:10.1002/dta.1377
   PubMed Web of Science ®Google Scholar
• Pertwee, R. (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9‐tetrahydrocannabinol, cannabidiol and Δ9‐tetrahydrocannabivarin. British Journal of Pharmacology, 153(2), 199–215. doi:10.1038/sj.bjp.0707442
   PubMed Web of Science ®Google Scholar
• Phan, K. L., Angstadt, M., Golden, J., Onyewuenyi, I., Popovska, A., & de Wit, H. (2008). Cannabinoid modulation of amygdala reactivity to social signals of threat in humans. Journal of Neuroscience, 28(10), 2313–2319. doi:10.1523/JNEUROSCI.5603-07.2008
   PubMed Web of Science ®Google Scholar
• Phillips, B., Ball, C., Badenoch, D., Straus, S., Haynes, B., & Dawes, M. J. B. I. (2011). Oxford centre for evidence-based medicine levels of evidence (May 2001). BJU International, 107(5), 870.
   PubMedGoogle Scholar
• Pietrzak, R. H., Huang, Y., Corsi-Travali, S., Zheng, M.-Q., Lin, S-F., Henry, S., … Neumeister, A. (2014). Cannabinoid type 1 receptor availability in the amygdala mediates threat processing in trauma survivors. Neuropsychopharmacology, 39(11), 2519–2528. doi:10.1038/npp.2014.110
   PubMed Web of Science ®Google Scholar
• Rabinak, C. A., Angstadt, M., Sripada, C. S., Abelson, J. L., Liberzon, I., Milad, M. R., & Phan, K. L. (2013). Cannabinoid facilitation of fear extinction memory recall in humans. Journal of Neuropharmacology, 64, 396–402. doi:10.1016/j.neuropharm.2012.06.063
   PubMed Web of Science ®Google Scholar
• Reznik, I. (2012). Post-traumatic stress disorder and medical cannabis use: A naturalistic observational study. European Neuropsychopharmacology, 22(suppl. 2), S363–S364. doi:10.1016/S0924-977X(12)70563-1
   Google Scholar
• Richardson, L. K., Frueh, B. C., & Acierno, R. (2010). Prevalence estimates of combat-related post-traumatic stress disorder: Critical review. Australian & New Zealand Journal of Psychiatry, 44(1), 4–19. doi:10.3109/00048670903393597
   PubMed Web of Science ®Google Scholar
• Rodriguez de Fonseca, F., Del Arco, I., Bermudez-Silva, F. J., Bilbao, A., Cippitelli, A., & Navarro, M. (2004). The endocannabinoid system: Physiology and pharmacology. Alcohol and Alcoholism, 40(1), 2–14. doi:10.1093/alcalc/agh110
   PubMed Web of Science ®Google Scholar
• Roitman, P., Mechoulam, R., Cooper-Kazaz, R., & Shalev, A. (2014). Preliminary, open-label, pilot study of add-on oral Δ 9-tetrahydrocannabinol in chronic post-traumatic stress disorder. Clinical Drug Investigation, 34(8), 587–591. doi:10.1007/s40261-014-0212-3
   PubMed Web of Science ®Google Scholar
• Ruehle, S., Rey, A. A., Remmers, F., & Lutz, B. (2012). The endocannabinoid system in anxiety, fear memory and habituation. Journal of Psychopharmacology, 26(1), 23–39. doi:10.1177/0269881111408958
   PubMed Web of Science ®Google Scholar
• Russo, E., & Guy, G. W. (2006). A tale of two cannabinoids: The therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Medical Hypotheses, 66(2), 234–246. doi:10.1016/j.mehy.2005.08.026
   PubMed Web of Science ®Google Scholar
• Russo, E. B., Burnett, A., Hall, B., & Parker, K. K. (2005). Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochemical Research, 30(8), 1037–1043. doi:10.1007/s11064-005-6978-1
   PubMed Web of Science ®Google Scholar
• Ryberg, E., Larsson, N., Sjögren, S., Hjorth, S., Hermansson, N.-O., Leonova, J., … Greasley, P. J. (2009). The orphan receptor GPR55 is a novel cannabinoid receptor. British Journal of Pharmacology, 152(7), 1092–1101. doi:10.1038/sj.bjp.0707460
   Web of Science ®Google Scholar
• Seeman, P. (2016). Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose. Translational Psychiatry, 6(10), e920. doi:10.1038/tp.2016.195
   PubMedGoogle Scholar
• Shannon, S., & Opila-Lehman, J. (2016). Effectiveness of cannabidiol oil for pediatric anxiety and insomnia as part of posttraumatic stress disorder: A case report. The Permanente Journal, 20(4), 108. doi:10.7812/TPP/16-005
   PubMedGoogle Scholar
• Steenkamp, M. M., Blessing, E. M., Galatzer-Levy, I. R., Hollahan, L. C., Anderson, W. T., M.M, S., … T, A. W. (2017). Marijuana and other cannabinoids as a treatment for posttraumatic stress disorder: A literature review. Depression and Anxiety, 34(3), 207–216. doi:10.1002/da.22596
   PubMed Web of Science ®Google Scholar
• Straiker, A., Dvorakova, M., Zimmowitch, A., & Mackie, K. P. (2018). Cannabidiol inhibits endocannabinoid signaling in autaptic hippocampal neurons. Molecular Pharmacology, 94(1), 743. doi:10.1124/mol.118.111864
   PubMed Web of Science ®Google Scholar
• Trezza, V., & Campolongo, P. (2013). The endocannabinoid system as a possible target to treat both the cognitive and emotional features of post-traumatic stress disorder (PTSD). Frontiers in Behavioral Neuroscience, 7, 1–5. doi:10.3389/fnbeh.2013.00100
   PubMed Web of Science ®Google Scholar
• Vandrey, R., Raber, J. C., Raber, M. E., Douglass, B., Miller, C., & Bonn-Miller, M. O. (2015). Cannabinoid dose and label accuracy in edible medical cannabis products. JAMA, 313(24), 2491–2493. doi:10.1001/jama.2015.6613
   PubMed Web of Science ®Google Scholar
• Viveros, M., Marco, E. M., & File, S. E. (2005). Endocannabinoid system and stress and anxiety responses. Pharmacology Biochemistry and Behavior, 81(2), 331–342. doi:10.1016/j.pbb.2005.01.029
   PubMed Web of Science ®Google Scholar
• Volkow, N. D., Hampson, A. J., & Baler, R. D. (2017). Don't worry, be happy: Endocannabinoids and cannabis at the intersection of stress and reward. Annual Review of Pharmacology and Toxicology, 57, 285–308. doi:10.1146/annurev-pharmtox-010716-104615
   PubMed Web of Science ®Google Scholar
• Walsh, Z., Gonzalez, R., Crosby, K., S. Thiessen, M., Carroll, C., & Bonn-Miller, M. O. (2017). Medical cannabis and mental health: A guided systematic review. Clinical Psychology Review, 51, 15–29. doi:10.1016/j.cpr.2016.10.002
   PubMed Web of Science ®Google Scholar
• Wilkinson, S. T., Radhakrishnan, R., & D’Souza, D. C. (2016). A systematic review of the evidence for medical marijuana in psychiatric indications. The Journal of Clinical Psychiatry, 77(08), 1050–1064. doi:10.4088/JCP.15r10036
   PubMedGoogle Scholar
• Wilkinson, S. T., Stefanovics, E., & Rosenheck, R. A. (2015). Marijuana use is associated with worse outcomes in symptom severity and violent behavior in patients with posttraumatic stress disorder. The Journal of Clinical Psychiatry, 76(09), 1174–1180. doi:10.4088/JCP.14m09475
   PubMedGoogle Scholar
• Woodhams, S. G., Sagar, D. R., Burston, J. J., & Chapman, V. (2015). The role of the endocannabinoid system in pain. In Pain control (pp. 119–143). Berlin, Heidelberg: Springer.
   Google Scholar
• Yehuda, R., & LeDoux, J. (2007). Response variation following trauma: A translational neuroscience approach to understanding PTSD. Neuron, 56(1), 19–32. doi:10.1016/j.neuron.2007.09.006
   PubMed Web of Science ®Google Scholar
• Zoladz, P. R., & Diamond, D. (2016). Predator-based psychosocial stress animal model of PTSD: Preclinical assessment of traumatic stress at cognitive, hormonal, pharmacological, cardiovascular and epigenetic levels of analysis. Experimental Neurology, 284, 211–219. doi:10.1016/j.expneurol.2016.06.003
   PubMed Web of Science ®Google Scholar